These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 27624314

  • 1. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y.
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [Abstract] [Full Text] [Related]

  • 2. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A, Bhargava R, Rai P, Aggarwal R.
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Chung W, Kim KA, Jang ES, Ki M, Choi HY, Jeong SH.
    J Gastroenterol Hepatol; 2019 Apr; 34(4):776-783. PubMed ID: 30462841
    [Abstract] [Full Text] [Related]

  • 4. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N.
    PLoS One; 2017 Apr; 12(7):e0179764. PubMed ID: 28704381
    [Abstract] [Full Text] [Related]

  • 5. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
    Sidhu SS, Malhi NS, Goyal O, Singh R, Dutta U, Grover R, Sidhu JS, Nanda V, Saluja H, Bansal A, Singh G, Sehgal A, Kishore H, Sidhu S.
    Hepatol Int; 2017 May; 11(3):277-285. PubMed ID: 28361300
    [Abstract] [Full Text] [Related]

  • 6. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A, Techasirioangkun T.
    PLoS One; 2020 May; 15(2):e0229517. PubMed ID: 32106270
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
    Larrey D, Carenco C, Guyader D, Boyer N, Benhamou Y, Pageaux GP, Rouzier R, Marcellin P.
    Antivir Ther; 2012 May; 17(5):927-32. PubMed ID: 22611092
    [Abstract] [Full Text] [Related]

  • 9. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
    Elsharkawy A, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, Said M, Motawea I, El Demerdash T, Seif S, Gaballah A, El Shazly Y, Makhlouf MA, Waked I, Abdelaziz AO, Yosry A, El Serafy M, Thursz M, Doss W, Esmat G.
    Aliment Pharmacol Ther; 2017 Mar; 45(5):681-687. PubMed ID: 28070899
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
    Shin HP, Burman B, Kozarek RA, Zeigler A, Wang C, Lee H, Zehr T, Edwards AM, Siddique A.
    Gut Liver; 2017 Sep 15; 11(5):711-720. PubMed ID: 28651301
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M, Domínguez-Hernández R, Oyagüez I, Casado MÁ.
    Gastroenterol Hepatol; 2016 Sep 15; 39(7):449-57. PubMed ID: 27084669
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Ahmed OA, Kaisar HH, Hawash N, Samir H, Shabana SST, Hassan A Fouad M, Rizk F, Abd-Elsalam S.
    Infect Disord Drug Targets; 2017 Sep 15; 17(2):95-100. PubMed ID: 28413993
    [Abstract] [Full Text] [Related]

  • 16. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH.
    Hepatol Int; 2018 Jul 15; 12(4):339-347. PubMed ID: 29663115
    [Abstract] [Full Text] [Related]

  • 17. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
    Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA.
    Enferm Infecc Microbiol Clin; 2013 Jul 15; 31(7):424-9. PubMed ID: 23453582
    [Abstract] [Full Text] [Related]

  • 18. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
    Pol S, Sulkowski MS, Hassanein T, Gane EJ, Liu L, Mo H, Doehle B, Kanwar B, Brainard D, Subramanian GM, Symonds WT, McHutchison JG, Nahass RG, Bennett M, Jacobson IM.
    Hepatology; 2015 Jul 15; 62(1):129-34. PubMed ID: 25847509
    [Abstract] [Full Text] [Related]

  • 19. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV, VITAL-1 study team.
    Hepatology; 2015 Oct 15; 62(4):1013-23. PubMed ID: 26118427
    [Abstract] [Full Text] [Related]

  • 20. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A, Midha V, Goyal O.
    Ann Hepatol; 2014 Oct 15; 13(5):503-9. PubMed ID: 25152982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.